Poolbeg Pharma Past Earnings Performance

Past criteria checks 0/6

Poolbeg Pharma has been growing earnings at an average annual rate of 10.5%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually.

Key information

10.5%

Earnings growth rate

10.5%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth raten/a
Return on equity-35.2%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

Aug 20
Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Feb 16
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Oct 05
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Jun 01
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Jul 12
Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Revenue & Expenses Breakdown

How Poolbeg Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:POLB Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-442
31 Mar 240-442
31 Dec 230-432
30 Sep 230-432
30 Jun 230-532
31 Mar 230-532
31 Dec 220-532

Quality Earnings: POLB is currently unprofitable.

Growing Profit Margin: POLB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if POLB's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare POLB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: POLB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).


Return on Equity

High ROE: POLB has a negative Return on Equity (-35.17%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies